New restrictions on functional claims for complementary medicines in Australia
Published: 12 Mar 2018
Following a 17 month process of consultation and legislative policy formation, the Therapeutic Goods Amendment (2017 Measures No. 1) Act 2018 (Cth) was assented to. This federal law reform will result in a list of permitted claims used in marketing functionality of a therapeutic product. The proposed list of claims is called the Low Level Indications List. This article elaborates on these reform laws and the implications.
Your current level of membership does not allow you access to this page.
To enquire about upgrading your access package please contact us.